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The O157 antigen of Escherichia coli shares structural elements with lipopolysaccharide (LPS) antigens of
other bacterial species, notably Brucella abortus and Yersinia enterocolitica O9, a fact that confounds the inter-
pretation of assays for anti-O157 antibodies. To address this problem, a blocking enzyme-linked immunosor-
bent assay (bELISA) was designed with E. coli O157:H7 LPS as the antigen and a monoclonal antibody specific
for E. coli O157, designated 13B3, as the competing antibody. The bELISA had equivalent sensitivity to, and
significantly higher specificity than, the indirect ELISA (iELISA), detecting anti-O157 antibodies in sera from
cattle experimentally inoculated with O157:H7. Only 13% of sera from naive heifers vaccinated for or exper-
imentally infected with B. abortus had increased anti-O157 bELISA titers, while 61% of anti-O157 iELISA titers
were increased. The bELISA is a sensitive and specific method for the detection of serum antibodies resulting
from exposure to E. coli O157.
Escherichia coli O157:H7 is a recently emergent pathogen
which is capable of causing severe disease and death in humans
(1). Serious outbreaks as well as sporadic cases of E. coli
O157:H7 infection resulting in hemorrhagic colitis, thrombo-
cytopenia, and hemolytic uremic syndrome have been reported
with increasing frequency since 1982 (5, 26). The gastrointes-
tinal tracts of clinically healthy cattle are major reservoirs of
E. coli O157:H7. Outbreaks have been associated with ground
beef as well as with various other foods, such as apple cider,
which may have been contaminated with bovine feces (1, 33).
Epidemiologic studies indicate that a significant proportion of
cattle herds contain individuals which shed E. coli O157:H7 in
their feces, suggesting a serious potential risk of meat and
environmental contamination (16). However, since fecal shed-
ding of E. coli O157:H7 by cattle is intermittent, the actual
prevalence of infection and the associated risks are likely to be
higher than estimates based on fecal cultures (3, 10, 14).
Given the intermittent nature of fecal shedding in cattle and
the limited duration of shedding in humans, it is logical that
other diagnostic techniques, such as serology, might be useful
adjuncts to bacteriologic culture methods for detecting infec-
tion with E. coli O157:H7. Both cattle and humans seroconvert
to O157 antigen following oral infection with E. coli O157:H7
(2, 19). Several studies have demonstrated the utility of anti-
O157-antibody detection in cases of hemorrhagic colitis and
hemolytic uremic syndrome where bacteriologic culture failed
to detect O157:H7 in feces (4, 7, 8). In addition, an association
between exposure to cattle and the prevalence of anti-O157
serum antibodies in healthy human populations has been doc-
umented (25). These studies used highly purified O157 lipo-
polysaccharide (LPS) antigen in indirect hemagglutination
or indirect enzyme-linked immunosorbent assays (iELISA)
to quantify anti-O157 serum antibodies, and these techniques
appear to be reasonably sensitive and specific when applied to
populations at risk. However, serologic cross-reactivity be-
tween E. coli O157 LPS and LPSs of several other gram-nega-
tive bacteria has been reported; this cross-reactivity brings about
false-positive results which complicate the interpretation of
clinical and epidemiologic studies utilizing these indirect tests.
Bacterial species known to cross-react with E. coli O157 LPS
include Escherichia hermannii, Citrobacter freundii, Salmonella
O301 (group N), Vibrio cholerae O1, Yersinia enterocolitica O9,
and Brucella abortus, as well as other E. coli O serotypes (6,
21–23). This cross-reactivity may affect both the specificity of
the results obtained from indirect tests and the sensitivity, as
indicated by the relatively high negative cutoff titers reported
for O157 iELISA (2, 19). The purpose of this study was to
determine the sensitivity and specificity of detection of anti-
O157 antibodies by utilizing highly O157-specific monoclonal
antibody (MAb) in a blocking ELISA (bELISA) format.
MATERIALS AND METHODS
Bacterial strains. E. coli O157:H7 (ATCC 43895) was utilized for preparation
of LPS antigen and for immunization of cattle. Calves were infected with E. coli
O157:H7 86-24, E. coli O157:H7 87-23 (a Shiga toxin type 2 negative variant
isolated from the same outbreak), or wild-type B. abortus (9, 17, 30). B. abortus
19 vaccine was obtained from a commercial source (Professional Biological Co.,
Denver, Colo.).
MAb. The production and characterization of MAb to O157 LPS has been
previously described (32). One immunoglobulin G3 (IgG3) MAb, designated
MARC 13B3, specific for an epitope of the O157 antigen not shared by B. abortus
or Y. enterocolitica, was selected in preliminary studies for development of the
bELISA.
LPS purification. Crude O157 LPS was prepared from a late-log-phase culture
in brain heart infusion media as previously described (20). Briefly, the suspen-
sions were washed twice with double-distilled H2O (ddH2O) and then resus-
pended in 2 ml of 0.25 M EDTA–0.5 M Tris-HCl (pH 7.2) and incubated at room
temperature for 30 min. After the volume had been adjusted to 10 ml with
ddH2O, the suspension was centrifuged (9,000 3 g, 10 min) and the pellet was
discarded. Crude LPS was precipitated from the supernatant by the addition of
2.5 vol of acetone, the resulting suspension was centrifuged at 10,000 3 g for 30
min, and the pellet was dried under vacuum and then resuspended in ddH2O.
Highly purified LPS was prepared from this suspension by ultracentrifugation
(105,000 3 g, 16 h) that was repeated until no UV (340 to 220 nm) absorption
peaks were detected (11). LPS prepared in this manner contained no detectable
protein and showed a typical distinct laddering pattern upon gel electrophoresis
(data not shown).
iELISA. iELISA was performed essentially as described by Reymond et al.
(25). Round-bottom 96-well plates (Immulon 2; Dynex, Chantilly, Va.) were
coated with 1 mg of purified LPS per ml in phosphate-buffered saline (PBS) (pH
7.2), first for 1 h at 37°C and then overnight at 4°C in a humidified chamber.
Plates were washed five times with PBS, blocked with 1% gelatin for 1 h at 37°C,
and washed again five times with PBS. Sample sera were initially diluted 1:80 and
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then diluted twofold in fluorescent trepomonal antibody hemagglutination buffer
(BBL Microbiology Systems, Cockeysville, Md.) with 0.1% Tween 80 and 0.5%
horse serum (PBS-T-HS). A total of 100 ml was added to wells and incubated for
1 h at 37°C, and the plates were washed five times with PBS-T-HS. Bound
anti-O157 antibody was detected by the addition of 100 ml of a 1:1,280 dilution
of peroxidase-labeled goat anti-bovine IgG heavy and light chain (Kirkegaard &
Perry Laboratories, Gaithersburg, Md.) and incubation at 37°C for 1 h, followed
by the addition of 100 ml of 0.3% 2,29-azino-di-[3-ethylbenzthiazoline sulfonate
(6)] (ABTS) (Kirkegaard & Perry Laboratories). After 15 min, the reaction was
stopped by adding 50 ml of 1% sodium dodecyl sulfate. The difference between
the specific optical density at 405 nm (OD405) and that at 490 nm, as measured
by an automated microplate reader (Bio-Tek Instruments Inc., Winooski, Vt.),
was used for analysis. Cutoff values were determined for pre- and postinoculation
sera from a subset of experimentally infected cattle by nonparametric receiver-
operator characteristic (ROC) analysis of the OD at a 1:320 sample dilution and
were comparable to those previously reported (15). Titer was defined as the
reciprocal of the highest twofold dilution of test serum resulting in an OD greater
than or equal to the cutoff value. All sera were tested in duplicate.
bELISA. Optimal concentrations of O157 LPS and MARC 13B3 MAb were
determined by checkerboard titration to provide near-maximal binding of
MARC 13B3. Plates were coated with highly purified LPS diluted in 0.5 mM
carbonate buffer, pH 9.6, for 1.5 h at 37°C and then washed five times with
PBS-T-HS. Sample sera were diluted twofold in PBS-T-HS, and 100 ml was
added to each well and incubated for 45 min at 37°C; then plates were washed six
times with PBS-T-HS. Ascites containing MARC 13B3 (100 ml of a 1:7,000
dilution) were added to each well and incubated for 15 min at 37°C; the plates
were washed six times with PBS-T-HS, and bound MARC 13B3 was detected by
the addition of 100 ml of peroxidase-labeled rabbit anti-mouse IgG diluted
1:1,500 (Kirkegaard & Perry Laboratories), incubation for 15 min, washing eight
times with PBS-T-HS, and the addition of 100 ml of ABTS for 15 min. The
reaction was stopped by adding 50 ml of 1% sodium dodecyl sulfate. Results were
expressed as percent inhibition of MARC 13B3 binding relative to the inhibition
caused by fetal calf serum (FCS) according to the following formula: [OD405/490
(FCS) 2 OD405/490 (sample)]/OD405/490 (FCS) 3 100 5 percent inhibition.
Cutoff values were determined with a subset of experimentally infected cattle
sera by nonparametric ROC analysis (15). Titer was defined as the reciprocal of
the highest twofold dilution of test serum resulting in percent inhibition greater
than 40.9% of the inhibition caused by FCS alone. Animals were considered
seropositive if they had bELISA or iELISA titers (21/log2) greater than or equal
to 2 or 6.3, respectively. All sera were tested in duplicate.
Animals. Three conventionally reared, 550-kg, mixed-breed beef steers were
immunized by three subcutaneous injections of 108 CFU of heat-killed E. coli
O157:H7, approximately 3 weeks apart. A group of 14 conventionally reared beef
calves were infected by oral inoculation of 1010 CFU of E. coli O157:H7. These
calves received three inoculations at 3-week intervals over a course of 7 weeks.
Five additional calves served as controls for the first 6 weeks and were inoculated
with E. coli O157:H7 during week seven. All cattle were negative by fecal culture
for E. coli O157:H7 prior to initiation of experiments. Animals which had pos-
itive preinoculation titers by both iELISA and bELISA were excluded from ROC
analysis (31). For evaluation of cross-reactivity in O157 ELISA tests, serum
samples were obtained from a herd of 20 mixed-breed beef heifers in central
Nebraska immediately prior to initial immunization with B. abortus 19 and again
42 days following immunization. Additional pre- and postinoculation samples
were obtained from three calves which were experimentally infected with wild-
type B. abortus.
Statistical analysis. Cutoff values and test sensitivity and specificity were
determined by nonparametric ROC analysis by the method of Greiner, executed
on an Excel 5.0 spreadsheet supplied by the author (15). Differences between
titers and inhibition percentages were evaluated by Mann-Whitney U test with
the Astute software module (University of Leeds, United Kingdom) and Excel
5.0 (Microsoft, Bellevue, Wash.). Proportions of animals responding serologi-
cally were compared by means of McNemar’s exact test with Yates’s correction
(27). Sensitivity, specificity, likelihood ratios, and confidence intervals (CIs) were
calculated by standard methods (12, 28). Reverse cumulative distribution plots
were generated by the method of Reed et al. (24).
RESULTS
Sera from experimentally infected calves strongly inhibited
binding of MARC 13B3 MAb to O157 LPS (Fig. 1). At a
dilution of 1:4, postinfection sera inhibited MARC 13B3 bind-
ing 92.8% 6 3.27% (mean 6 standard error of the mean
[SEM]; range, 70 to 97%), while preinfection sera inhibited
binding 8.7% 6 3.94% (range, 0.25 to 35%). Inhibition by
postinfection sera was significantly greater than by correspond-
ing dilutions (up to 1:256) of preinfection sera (P # 0.05).
Postinfection sera at dilutions of 1:64 inhibited MARC 13B3
binding significantly more than 1:4 dilutions of preinfection
sera (P # 0.05). Nonparametric ROC analysis of inhibition by
1:4 dilutions of pre- and postinfection sera resulted in a point
estimate optimum cutoff value of 40.9% inhibition of MARC
13B3 binding (95% CI 5 15 to 84%). ROC analysis of the
absorbance values from iELISA tests performed with 1:320
dilutions of the same serum samples resulted in a point esti-
FIG. 1. Inhibition of MAb MARC 13B3 binding to E. coli O157:H7 LPS by
immune and nonimmune cattle sera. Points are averages 6 SEM, n 5 19.
FIG. 2. Serum antibody responses to E. coli O157 antigen of calves infected per os (n 5 19) or immunized (n 5 3) with E. coli O157:H7. (A) Paired pre- and
postinfection/immunization bELISA and iELISA titers. Summary box plots indicate the median titer (solid line), 25 to 75% range (box), and 5 to 95% range (error
bars) for each set of titers. Open symbols indicate data points outside the 5 to 95% range. (B) Cumulative distribution of anti-O157 bELISA and iELISA titers of calves
infected orally with E. coli O157:H7 (n 5 19) or immunized with heat-killed E. coli O157:H7 (n 5 3).
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mate optimum cutoff value of 1.21 A405 (95% CI 5 0.44 to
1.69). These values were used to define titer endpoints.
Prior to oral infection or parenteral immunization with
E. coli O157:H7, significantly fewer cattle (3 of 22) were sero-
positive by bELISA than were positive by iELISA (12 of 22;
P 5 0.008). Mean titers (21/log2) 6 SEM for positive cattle
were 2.25 6 0.25 and 7.59 6 0.42 for bELISA and iELISA,
respectively. All cattle were seropositive by both tests 10 to 12
weeks postinoculation, with average titers of 4.09 6 0.25
(bELISA) and 9.66 6 0.21 (iELISA). Average increase in titer
(mean difference between pre- and postinoculation titers) was
2.91 6 0.25 and 3.41 6 0.37, respectively (Fig. 2A). The cu-
mulative distributions of titers, normalized to cutoff, as mea-
sured by bELISA and iELISA were not different (Fig. 2B).
Sensitivities of both the bELISA and the iELISA were 100%
on this set of samples. Specificity of the bELISA was 86.4%
(95% CI, 72 to 100%) while the specificity of the iELISA was
45.5% (95% CI, 24.6 to 66.3%). Likelihood ratios for bELISA
and iELISA were 7.3 (95% CI, 5.4 to 9.2) and 1.83 (95% CI,
0.1 to 3.7), respectively, based on pre- and postinoculation
titers. bELISA and iELISA evaluations of antibody responses
to experimental oral infection of a subset of calves monitored
over time were parallel (Fig. 3).
All 23 animals in a group of cattle were seropositive to O157
by iELISA, with a mean titer (6 SEM) of 7.65 6 0.20, prior to
vaccination with B. abortus 19 or experimental infection with
wild-type B. abortus. Following infection or vaccination, 20 of
23 animals had increases in iELISA titer; the mean increase
was 1.96 6 0.24 (P 5 0.043), significantly increasing the group
mean titer to 9.60 6 0.25 (P 5 0.001) (Fig. 4A). Only 12 of 23
cattle were anti-O157 seropositive by bELISA, with a mean
titer of 3.25 6 0.28. The proportion of animals seropositive
for O157 by bELISA (12 of 23) did not increase following
B. abortus infection or vaccination; though three animals did
have increased titers, this did not significantly affect the group
mean titer of 3.42 6 0.19 (Fig. 4A). Cumulative distribution of
bELISA titers did not change, while a clear shift to higher
cumulative iELISA titers is evident following B. abortus infec-
tion or immunization (Fig. 4B). The induction of cross-reactive
antibodies following B. abortus vaccination was confirmed by
Western blots in which reactivity to O antigen of O157 LPS
was present with post- but not prevaccination sera (data not
shown).
DISCUSSION
Specificity is a critical element of serologic testing, especially
in cases where supportive data, such as culture or epidemio-
logic associations, may be lacking. The bELISA described in
this study is based on a MAb for the E. coli O157 antigen which
lacks cross-reactivity with other E. coli serotypes and with anti-
gens of other gram-negative bacteria which share determinants
with O157, such as Y. enterocolitica O9 and B. abortus (32). Use
of this MAb in the bELISA format provides a high level of
specificity for serologic testing of anti-O157 antibody. This is
best demonstrated by results obtained with sera from cattle ex-
perimentally infected with or vaccinated against B. abortus.
Increased iELISA titers against O157, compared to prevac-
cination titers, were present in B. abortus-immune cattle, and
antibodies cross-reactive with O antigen were detected by West-
ern blot that had detected E. coli O157 LPS. These cross-reac-
tive antibodies did not affect bELISA titers, confirming the
specificity of this assay. Although sera from animals infected
with other bacteria which cross-react with E. coli O157 were
not tested, results similar to those obtained with B. abortus
antisera would be expected based on the specificity of the MAb
MARC 13B3. An exception to this would be animals infected
with group N Salmonella spp. which have O antigens identical
FIG. 3. Serologic responses of calves (n 5 3) following oral inoculation with
E. coli O157:H7 86-24, as indicated by bELISA and iELISA titers. Points are
geometric means 6 SEM.
FIG. 4. Serum antibody reactivity to E. coli O157 antigen of calves vaccinated (n 5 20) or infected (n 5 3) with B. abortus. (A) Paired pre- and postvaccination/
infection bELISA and iELISA titers. Summary box plots indicate the median titer (solid line), 25 to 75% range (box), and 5 to 95% range (error bars) for each set
of titers. Open symbols indicate data points outside the 5 to 95% range. (B) Cumulative distribution of anti-O157 bELISA and iELISA titers of calves vaccinated with
B. abortus 19 (n 5 20) or infected with wild-type B. abortus (n 5 3).
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to those of E. coli O157 (22). Differentiation of these infections
on the basis of serologic response to O antigens, regardless of
test format, will be problematic. Fortunately, group N Salmo-
nella are not commonly isolated from cattle or other livestock
species in the United States (13).
The O157 bELISA format has several advantages, other
than specificity, over iELISA. First, the lack of cross-reactivity
allows for efficient, single-dilution screening of serum samples,
greatly increasing sample throughput for serologic surveys.
Second, sera from species other than cattle can be used with
this format without modification, which facilitates its use with
other livestock species, and with wildlife and humans (data not
shown). Third, the format includes negative-control informa-
tion in the calculations, resulting in internal normalization
which simplifies comparisons between assays done on different
plates or at different times. These attributes contribute to the
overall usefulness of the O157 bELISA for diagnostic and
epidemiologic applications.
Calves have been shown to seroconvert strongly and persis-
tently to O157 antigen following experimental infection with
E. coli O157:H7 (19). The effect of seroconversion to O157 on
B. abortus serology was recognized by Stuart and Corbel, who
described positive B. abortus agglutination tests with sera from
rabbits immunized against E. coli O157 as well as with sera
from cattle experimentally infected with E. coli O157 (29). The
significance of this finding was recently challenged by Johnson
et al., who found that cross-reactivity to B. abortus was rare in
cattle naturally infected with E. coli O157:H7 (18). The dis-
crepancies between these studies may be ascribed to differ-
ences in infectious dose, subtle differences in technique, or
other factors. It is clear from the present study, however, that
there are O157-cross-reactive antibodies induced by either vac-
cination or experimental infection of cattle with B. abortus and
that these antibodies have the potential to significantly influ-
ence the results of O157 iELISA tests. It is possible that in-
fection of cattle with other bacteria which cross-react with
O157 could give similar false-positive results on O157 iELISA
tests. The specificity of the O157 bELISA should allow for a
greater degree of confidence in a positive test result.
In conclusion, a bELISA for anti-O157 antibodies has been
developed which has a high degree of specificity and a sensi-
tivity equivalent to that of the less specific iELISA and which
is applicable to cattle and other species. This serologic test will
be a useful tool for clinical diagnosis and epidemiologic studies
of E. coli O157 infections of cattle and other livestock, with
potential for use with other species, including humans. Given
the limited duration and intermittent nature of shedding of
E. coli O157:H7 in cattle, development of the anti-O157 anti-
body-specific bELISA test provides an important new tool for
epidemiologic studies of E. coli O157 infections.
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